Cantor Fitzgerald Reiterates Overweight on Ascendis Pharma, Maintains $152 Price Target

Benzinga · 09/15/2023 12:36
Cantor Fitzgerald analyst Li Watsek reiterates Ascendis Pharma (NASDAQ:ASND) with a Overweight and maintains $152 price target.